Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non-small-cell lung cancer: The MILES-2P studies

Journal of Clinical Oncology

Volumn 25, Issue 29, 2007, Pages 4663-4669

  Gridelli, Cesare ^a   Maione, Paolo ^b   Illiano, Alfonso ^b   Piantedosi, Franco Vito ^b   Favaretto, Adolfo ^b   Bearz, Alessandra ^b   Robbiati, Sergio Federico ^b   Filipazzi, Virginio ^b   Lorusso, Vito ^b   Carrozza, Francesco ^b   Iaffaioli, Rosario Vincenzo ^b   Manzione, Luigi ^b   Gallo, Ciro ^b   Morabito, Alessandro ^b   Perrone, Francesco ^b  

^a S G MOSCATI HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE;

ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG FEVER; DRUG HYPERSENSITIVITY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC PATIENT; HAIR LOSS; HEART RHYTHM; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; NEUTROPENIC INFECTION; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VINBLASTINE;

EID: 35648937612     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.5708     Document Type: Article

References (30)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2:533-543, 2001
2. Survelliance, Epidemiology, and End Results (SEER): Cancer Statistics Review 1975-2004, National Cancer Institute. Bethesda, MD. http://www.seer. cancer.gov/csr/1975_2004/
3. The Elderly Lung Cancer Vinorelbine Italian Study Group: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non small cell lung cancer. J Natl Cancer Inst 91:66-72, 1999
4. Gridelli C, Perrone F, Gallo C, et al: Chemotherapy for elderly patients with advanced nonsmall-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362-372, 2003
5. Gridelli C, Aapro M, Ardizzoni A, et al: Treatment of advanced non-small-cell lung cancer in the elderly: Results of an International Expert Panel. J Clin Oncol 23:3125-3137, 2005
6. Pfister DG, Johnson DH, Azzoli CG, et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22:330-353, 2004
7. Minami H, Ohe Y, Niho S, et al: Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients: Why is toxicity increased in elderly patients? J Clin Oncol 22:2901-2908, 2004
8. Langer CJ, Manola J, Bernardo P, et al: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173-181, 2002
9. Kubota K, Furuse K, Kawahara M, et al: Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 40:469-474, 1997
10. Chen TT, Tie-Hua NG: Optimal flexible designs in phase II clinical trials. Stat Med 17:2301-2312, 1998
11. Langer CJ, Vangel M, Schiller J, et al: Age-specific subanalysis of ECOG 1594: fit elderly patients (70-80 yrs) with NSCLC do as well as younger pts (< 70). Proc Am Soc Clin Oncol 22:639, 2003 (abstr 2571)
12. Kelly K, Giarritta S, Hayes S, et al: Should older patients receive combination chemotherapy for advanced stage non-small cell lung cancer? An analysis of Southwest Oncology trials 9509 and 9308. Proc Am Soc Clin Oncol 20:329a, 2001 (abstr 1313)
13. Belani CP, Fossella F: Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 104:2766-2774, 2005
14. Lilenbaum RC, Herndon JE, List M, et al: Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: A CALGB randomized trial of efficacy, quality of life, and cost-effectiveness. J Clin Oncol 23:190-196, 2005
15. Hensing TA, Peterman AH, Schell MJ, et al: The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV non small cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 98:779-788, 2003
16. Ramalingam S, Barstis J, Perry MC, et al: Treatment of elderly non-small cell lung cancer patients with three different schedules of weekly paclitaxel in combination with carboplatin: Subanalysis of a randomized trial. J Thorac Oncol 1:240-244, 2006
17. Perrone F, Gallo C, Gridelli C: Re: Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:1029-1030, 2002
18. Jatoi A, Hillman S, Stella P, et al: Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the north Central Cancer Treatment Group. J Clin Oncol 23:9113-9119, 2005
19. Ohe Y, Niho S, Kakinuma R, et al: A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small cell lung cancer in elderly patients. Ann Oncol 15:45-50, 2004
20. Maestu IC, Gomez-Aldaravì L, Torregrossa MD, et al: Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer 42:345-354, 2003
21. Okamoto I, Moriyama E, Kishi H, et al: Multicenter phase II study of the combination of carboplatin and paclitaxel as first line treatment in elderly patients with advanced non small cell lung cancer. Proc Am Soc Clin Oncol 23:672, 2004 (abstr 7239)
22. Choi IS, Kim BS, Park SR, et al: Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non small cell lung cancer. Lung Cancer 39:99-101, 2003
23. Molinier O, Milleron B, Breton JL, et al: Multicenter phase II trial of carboplatin and weekly pacitaxel as first-line treatment in elderly patients with non small cell lung cancer: Preliminary results. Proc Am Soc Clin Oncol 22:693, 2003 (abstr 2786)
24. Inoue A, Usui, K, Ishimoto O, et al: A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer. Lung Cancer 52:83-87, 2006
25. Takatani H, Kinoshita A, Fukuda M, et al: A phase II study of vinoreline (VNR) and carboplatin (CBDCA) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 24:18S, 2006 (abstr 17108)
26. Tsukada H, Yokoyama A, Nishiwaki Y, et al: Randomized controlled trial comparing docetaxel (D)-cisplatin (P) combination with D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): JCOC0207. J Clin Oncol 25:18S, 2007 (7629 abstr)
27. Feliu J, Martin G, Madronal C, et al: Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non small cell lung cancer. Cancer Chemother Pharmacol 52:247-252, 2003
28. Berardi R, Porfiri E, Scartozzi M, et al: Elderly patients with advanced non-small cell lung cancer: A phase II study with weekly cisplatin and gemcitabine. Oncology 65:198-203, 2003
29. Shepherd FA, Abratt R, Crinò L, et al: The influence of gemcitabine and cisplatin schedule on response and survival in advanced non small cell lung cancer. Lung Cancer 30:117-125, 2000
30. Sederholm C, Hillerdal G, Lamberg K, et al: Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish lung cancer study group. J Clin Oncol 23:8380-8388, 2005